Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of LK101 Monotherapy in Participants With Advanced Solid Tumors to Evaluate the Safety, Tolerability, and Immunogenicity

NCT06054932 is registered in ClinicalTrials.gov with Beijing Likang Life Science and Tech Co., Ltd. as lead sponsor.

NCT NCT06054932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06054932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of LK101 Monotherapy in Participants With Advanced Solid Tumors to Evaluate the Safety, Tolerability, and Immunogenicity
Lead sponsor
Beijing Likang Life Science and Tech Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
September 5, 2023
Completion date
March 30, 2026
Enrollment
18 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor